Lilly, Valneva, AstraZeneca, Revvity, Merck

2023-06-02 07:00:00

AI: Lilly will collaborate with XtalPi

Eli Lilly will join forces with the Chinese company specializing in artificial intelligence and robotics, XtalPi. The goal is to discover new drug candidates against an undisclosed target. Specifically, Lilly will gain access to ID4Inno, XtalPi’s AI-powered small molecule discovery platform, in exchange for upfront and milestone payments potentially up to $250 million ($235 million). The laboratory will be solely in charge of clinical and commercial development.

Valneva files an MA application in Canada

The Nantes-based biotech has just filed an MA application with Health Canada for its candidate vaccine against chikungunya, VLA1553. This request is in addition to the one already made to the FDA in 2023. In Europe, Valneva plans to file for marketing authorization in the second half of 2023. VLA1553 is currently the only chikungunya vaccine candidate for which a regulatory process is underway.


AstraZeneca signs license agreement with Revvity

AstraZeneca got along with Revvity, the new company born in May 2023 and spun off from PerkinElmer’s life science and diagnostics business, to gain access to its genome-editing technology, called Pin-point. For the British laboratory, the objective is in particular the development of new cellular therapies for the treatment of cancer and immune-mediated diseases. Financial details of the deal were not disclosed.

Merck expands in Scotland

Merck (Merck KgaA) will invest 35 million euros at its Scottish sites in Glasgow and Stirling, to strengthen its analytical testing services capabilities, particularly related to biological risk, viral safety and analytical development. The major part of this investment will be devoted to the creation of new premises of 1,200 m² in Glasgow which will house sequencing and molecular biology services. Nearly 500 new jobs should be created in this way. Before Scotland, Merck had announced investments in this area in the United States in 2022, with €290 million injected in Rockville, Maryland and in China, via the opening of a site in Shanghai, for an amount of €29 M€.

Selected for you

NASH: Green light in China for the evaluation of lanifibranor from Dijon biotech Inventiva

#Lilly #Valneva #AstraZeneca #Revvity #Merck

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.